EMPA-REG OUTCOME: The Cardiologist's Point of View

American Journal of Cardiology

Volumn 120, Issue 1, 2017, Pages S53-S58

  Pham, Son V ^a   Chilton, Robert J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; CARDIOLOGIST; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DIABETIC PATIENT; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART WORK; HEMODYNAMICS; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; METABOLISM; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; RISK FACTOR;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCOSIDES; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIUM; OXYGEN CONSUMPTION; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; VENTRICULAR FUNCTION, LEFT;

EID: 85020395878     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.05.011     Document Type: Article

References (39)

1. 1 Gaede, P., Vedel, P., Parving, H.H., Pedersen, O., Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999), 617–622.
2. 2 Gaede, P., Oellgaard, J., Carstensen, B., et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59 (2016), 2298–2307.
3. 3 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
4. 4 Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
5. 5 Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
6. 6 Wanner, C., EMPA-REG OUTCOME: the nephrologist's point of view. Am J Cardiol 120:suppl 1 (2017), S59–S67.
7. 7 Staels, B., Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms of action. Am J Cardiol 120:suppl 1 (2017), S28–S36.
8. 8 Braunwald, E., 50th anniversary historical article. Myocardial oxygen consumption: the quest for its determinants and some clinical fallout. J Am Coll Cardiol 34 (1999), 1365–1368.
9. 9 Valentinuzzi, M.E., Kohen, A.J., Laplace's law: what it is about, where it comes from, and how it is often applied in physiology. IEEE Pulse 2 (2011), 74–84.
10. 10 Lehrke, M., Marx, N., Diabetes mellitus and heart failure. Am J Cardiol 120:suppl 1 (2017), S37–S47.
11. 11 Kasznicki, J., Drzewoski, J., Heart failure in the diabetic population - pathophysiology, diagnosis and management. Arch Med Sci 10 (2014), 546–556.
12. 12 Seferović, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36 (2015), 1718–1727 1727a-1727c.
13. 13 Yelle, D., Chaudhry, S., Heart failure (McMaster Pathophysiology Review). Available at: http://www.pathophys.org/heartfailure/ Accessed January 18, 2017.
14. 14 Kass, D.A., Age-related changes in venticular-arterial coupling: pathophysiologic implications. Heart Fail Rev 7 (2002), 51–62.
15. 15 Antonini-Canterin, F., Carerj, S., Di Bello, V., et al. Arterial stiffness and ventricular stiffness: a couple of diseases or a coupling disease? A review from the cardiologist's point of view. Eur J Echocardiogr 10 (2009), 36–43.
16. 16 Borlaug, B.A., Kass, D.A., Ventricular-vascular interaction in heart failure. Heart Fail Clin 4 (2008), 23–36.
17. 17 Kass, D.A., Ventricular arterial stiffening: integrating the pathophysiology. Hypertension 46 (2005), 185–193.
18. 18 Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
19. 19 Niiranen, T.J., Kalesan, B., Hamburg, N.M., Benjamin, E.J., Mitchell, G.F., Vasan, R.S., Relative contributions of arterial stiffness and hypertension to cardiovascular disease: the Framingham Heart Study. J Am Heart Assoc, 5(11), 2016 pii: e004271.
20. 20 Thompson, B., Towler, D.A., Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 8 (2012), 529–543.
21. 21 Towler, D.A., Commonalities between vasculature and bone: an osseocentric view of arteriosclerosis. Circulation 135 (2017), 320–322.
22. 22 Lyle, A.N., Raaz, U., Killing me unsoftly: causes and mechanisms of arterial stiffness. Arterioscler Thromb Vasc Biol 37 (2017), e1–e11.
23. 23 Stabley, J.N., Towler, D.A., Arterial calcification in diabetes mellitus: preclinical models and translational implications. Arterioscler Thromb Vasc Biol 37 (2017), 205–217.
24. 24 Storgaard, H., Gluud, L.L., Bennett, C., et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One, 11, 2016, e0166125.
25. 25 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
26. 26 Chilton, R., Gullestad, L., Fitchett, D., et al. Empagliflozin reduces markers of arterial stiffness, vascular resistance and cardiac workload in EMPA-REG OUTCOME. Circulation, 134, 2016 (A13520).
27. 27 Tikkanen, I., Chilton, R., Johansen, O.E., Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 25 (2016), 81–86.
28. 28 Abdul-Ghani, M., Del Prato, S., Chilton, R., DeFronzo, R.A., SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 39 (2016), 717–725.
29. 29 Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.
30. 30 Townsend, R.R., Machin, I., Ren, J., et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 18 (2016), 43–52.
31. 31 Weber, M.A., Mansfield, T.A., Cain, V.A., Iqbal, N., Parikh, S., Ptaszynska, A., Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 (2016), 211–220.
32. 32 Cook, N.R., Cohen, J., Hebert, P.R., Taylor, J.O., Hennekens, C.H., Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 155 (1995), 701–709.
33. 33 Hardy, S.T., Loehr, L.R., Butler, K.R., et al. Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control. J Am Heart Assoc, 4, 2015, e002276.
34. 34 Gori, T., Floras, J.S., Parker, J.D., Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol 40 (2002), 2000–2005.
35. 35 Habibi, J., Aroor, A.R., Sowers, J.R., et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol, 16(1), 2017, 9.
36. 36 Zile, M.R., Baicu, C.F., Gaasch, W.H., Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004), 1953–1959.
37. 37 Ernande, L., Derumeaux, G., Diabetic cardiomyopathy: myth or reality?. Arch Cardiovasc Dis 105 (2012), 218–225.
38. 38 Yonaha, O., Matsubara, T., Naruse, K., et al. Effects of reduced coronary flow reserve on left ventricular function in type 2 diabetes. Diabetes Res Clin Pract 82 (2008), 98–103.
39. 39 Taqueti, V.R., Hachamovitch, R., Murthy, V.L., et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 131 (2015), 19–27.